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Abstract  The  leading  causes  of  chronic  liver  disease  associated  with  HCC  are  hepatitis  B  and  C
viruses throughout  the  world,  and  alcohol  and  NASH  in  France.  After  increasing  for  20—30  years
in France,  the  rise  in  the  incidence  of  HCC  appears  to  be  slowing  and  the  death  rates  appear
to be  falling.  Screening  for  HCC  by  liver  ultrasound  is  performed  every  6  months.  Assay  of
serum alpha-fetoprotein  has  no  beneﬁt.  In  developed  countries,  failure  to  identify  patients
with cirrhosis  and  inadequate  adherence  to  guidelines  greatly  reduces  the  effectiveness  of
screening  for  HCC.
©  2014  Published  by  Elsevier  Masson  SAS  on  behalf  of  the  Éditions  françaises  de  radiologie.
Epidemiology and risk factors
Epidemiology
HCC  almost  always  develops  in  patients  suffering  from  chronic  liver  disease,  usually  at
the  cirrhotic  stage.  Its  epidemiology  is  therefore  closely  related  to  that  of  the  causes
of  cirrhosis  [1]: chronic  viral  hepatitis  B  (HBV)  and  C  (HCV)  infections,  excessive  alcohol
consumption  and  nonalcoholic  steatohepatitis  (NASH).
Viral  causes  predominate  throughout  the  world  and  approximately  80%  of  cases  of
HCC  are  found  in  areas  where  HBV  is  highly  endemic  (Asia  and  Africa),  often  associ-
ated  with  ingestion  of  aﬂatoxin  B1,  a  potently  carcinogenic  mycotoxin.  The  incidence
of  HCC  should  be  reduced  by  improving  storage  conditions  for  cereals  and  large-scale
vaccination  of  newborns  against  HBV.  This  vaccination  was  set  up  in  Taiwan  almost
30  years  ago  and  has  produced  a  spectacular  fall  in  the  number  of  cases  of  HCC
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n  children  and  young  adults  [2].  The  epidemiology  of  HCC
s  very  different  in  France,  as  the  main  cause  of  cirrhosis
nd  HCC  (two-thirds  of  cases)  is  excessive  alcohol  consump-
ion  [1].  NASH  is  increasingly  responsible  because  of  the
ncreased  prevalence  of  obesity  and  diabetes.  The  number
f  cases  of  NASH-related  HCC  currently  appears  to  be  similar
o  the  number  associated  with  HCV  [3].
Although  the  incidence  of  HCC  appears  to  be  falling  in
frica  and  Asia,  the  same  does  not  apply  in  the  Western
orld,  where  both  its  incidence  and  mortality  rates  have
ncreased  greatly  over  recent  years.  This  rise  appears  to  be
ue  to  patients  infected  with  HCV  in  the  1970—1980s  reach-
ng  the  cirrhotic  stage  and  to  the  reduction  in  mortality  from
he  other  complications  of  cirrhosis  (gastrointestinal  bleeds
nd  bacterial  infection)  leaving  patients  exposed  for  longer
o  the  risk  of  developing  HCC  [1].
isk factors
irrhosis,  regardless  of  its  cause,  is  the  main  risk  factor
or  HCC  with  an  individual  risk  of  2  to  6%  annually,  which
s  inﬂuenced  by  many  other  factors  [4].  Risk  is  greater  in
atients  with  HCV  cirrhosis  than  in  those  with  alcoholic  or
BV  cirrhosis.  The  risk  from  similar  viral  causes  is  higher  in
sia  than  in  the  Western  world  and  is  also  inﬂuenced  by  sex
male),  age  (>  55-years-old),  severity  of  the  liver  disease,
erum  alpha-fetoprotein  (AFP)  concentration,  and  comor-
idities  (alcohol,  obesity,  diabetes  and  HIV).  Simple  clinical
nd  laboratory  scores  can  be  used  to  separate  patients  suf-
ering  from  cirrhosis  into  several  groups  at  very  different
isks  of  HCC  [1].
If  cirrhosis  is  not  present,  the  risk  of  developing  HCC  is
xtremely  low  in  alcoholic  and  HCV  disease  and  higher  for
BV  and  NASH  (40%  of  cases)  [5].
creening
nly  a  small  HCCs  (Milan  criteria:  a  single  nodule  under  5  cm
n  diameter  or  2  to  3  nodules  under  3  cm  in  diameter)  are
menable  to  curative  treatment.  As  the  tumors  are  asymp-
omatic,  they  need  to  be  screened  for  by  periodic  monitoring
n  at  risk  patients  [6].
cademic studies
hese  have  clariﬁed  the  screening  methods  [6].  The  major
arget  is  patients  suffering  from  cirrhosis  regardless  of
ause,  alcohol,  HCV,  HBV  and  NASH,  and  those  with  inherited
emochromatosis,  autoimmune  hepatitis  and  primary  biliary
irrhosis.  As  the  aim  is  to  offer  curative  therapy,  patients
ith  contraindications  to  this  are  not  therefore  affected.
hilst  there  are  many  contraindications  to  surgery  (trans-
lantation  and  resection),  percutaneous  ablation  therapies
an  be  used  in  a  large  number  of  patients.  Screening  is  not
ndicated  if  the  cirrhosis  is  decompensated  as  the  major
rognostic  indicator  in  this  situation  is  the  severity  of  the
irrhosis,  unless  the  patient  is  awaiting  transplantation,  in
hich  development  of  an  HCC  changes  the  transplant  allo-
ation  rules.
Screening  for  HCC  is  still  based  on  a  standard  liver  ultra-
ound  performed  every  6  months  [6].  There  is  no  evidence  to
T
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horten  this  period,  which  is  based  on  the  aggressive  nature
f  the  tumor  and  not  on  actual  risk  [7]. Measurement  of  AFP
s  of  little  beneﬁt  as  the  majority  of  small  HCC  are  not  asso-
iated  with  a  rise  in  serum  AFP  concentrations.  If  a  focal
esion  is  found  on  screening,  diagnostic  investigations  need
o  be  performed  with  enhanced  CT  and/or  MRI  and  pos-
ibly  a guided  biopsy.  Unlike  other  solid  tumors,  HCC  can
e  diagnosed  without  histological  evidence  (probabilistic
iagnosis),  if  imaging  shows  typical  appearance  (hypervas-
ularized  nodule  in  the  arterial  phase  with  washout  in  the
ortal  and/or  late  phase)  [6].  This  typical  appearance  is
nly  rarely  found  if  the  nodule  is  small  (under  10  mm  in
iameter).  This  is  an  important  limitation  as  small  nodules
urrently  account  for  up  to  40%  of  focal  lesions  found  on
creening  [7].  If  the  nature  of  the  nodule  has  not  been  estab-
ished,  it  is  essential  to  continue  monitoring  to  detect  any
ncrease  in  size.  Ultrasound  cannot  be  performed  in  10%  of
atients  (because  of  obesity),  in  which  case  MRI  is  recom-
ended.
Periodic  screening  detects  up  to  75%  of  tumors  at  a
tage,  which  is  amenable  to  curative  treatment  [7].  One
andomized  trial  (of  poor  methodological  quality)  has  shown
mproved  survival  in  patients  who  were  screened  [8].  Inter-
stingly,  survival  in  patients  undergoing  the  same  screening
ethods  increased  over  time,  probably  due  to  more  effec-
ive  curative  therapy  [9].
tudies in the general population
s  in  other  countries,  screening  for  HCC  is  not  used  suf-
ciently  in  France.  One  recent  French  study  (the  Changh
bservational  study)  showed  that  only  25%  of  patients
eceived  curative  treatment  and  that  only  20%  of  patients
ere  screened  before  the  diagnosis  of  their  cancer  [3],  in
ontrast  to  the  ﬁndings  from  the  academic  studies.
The  effectiveness  of  screening  relies  on  several  suc-
essive  stages:  identiﬁcation  of  patients  suffering  from
irrhosis,  screening  of  these  patients  for  HCC  using  rec-
mmended  methods  and  the  appropriate  use  of  curative
reatments.  Identifying  patients  suffering  from  compen-
ated  cirrhosis,  who  are  usually  asymptomatic,  can  be
acilitated  by  ‘non  invasive’  methods  such  as  blood  tests
Fibrotest®,  Fibromètre®) and  the  Fibroscan®. Even  when
irrhosis  is  found,  periodic  screening  appears  to  be  used
nappropriately:  almost  40%  of  patients  suffering  from  HCC
ave  not  had  appropriate  screening  despite  the  fact  that
heir  cirrhosis  was  known  [10],  probably  because  of  doctors
ot  being  aware  of  guidelines  or  being  sceptical  about  the
ffectiveness  of  screening.  The  Changh  study  results  also
uggest  that  percutaneous  ablation  is  still  underused,  as
he  proportion  of  patients  treated  with  this  method  (which
as  few  contraindications)  was  similar  to  the  proportion
f  patients  undergoing  resection  or  transplantation  (which
ave  many  contraindications)  [3].he  indications  for  treatment  depend  on  the  size  and  exten-
ion  of  the  tumor,  the  condition  of  the  non-tumor  liver
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parenchyma  and  the  patient’s  general  health  [6].  In  view
of  the  diagnostic  difﬁculties  (particularly  if  the  nodule  is
small)  and  complexity  of  the  indications  for  treatment,  it
would  appear  essential  for  the  patient’s  case  to  be  discussed
in  a  specialist  multidisciplinary  team  meeting  (MDT).  These
MDT  should  offer  all  of  the  available  treatment  options  and
therefore,  in  addition  to  medical  oncologist  and  pathologist,
include  hepatologist,  interventional  radiologist  experienced
in  percutaneous  ablation  techniques  and  transplant  surgeon.
Curative treatment
Patients  eligible  for  transplantation  are  those  who  meet
the  Milan  criteria  with  compatible  age  (<  65—70-years-old)
and  general  health.  Because  of  the  long  waiting  time,
arterial  chemoembolization,  percutaneous  ablation  or  even
resection  have  been  proposed  to  control  tumor  growth
before  transplantation  [6].  Some  patients  suffering  from
HCC  who  do  not  meet  the  Milan  criteria  have  been  trans-
planted  with  satisfactory  results,  which  has  led  to  a  proposal
that  the  eligibility  criteria  should  be  extended.  Prior  treat-
ment  with  arterial  chemoembolization  or  radiofrequency
ablation  (‘downstaging’)  may  allow  patients  who  were  inel-
igible  to  be  transplanted  secondarily  [6].
Because  of  the  high  prevalence  of  contraindications  to
transplantation,  local  therapy  is  often  the  only  option  for
the  tumor.  There  are  few  candidates  for  resection  (normal
serum  bilirubin,  no  portal  hypertension)  [6]  and  conven-
tional  (monopolar)  percutaneous  radiofrequency  ablation  is
used  for  the  limited  number  of  patients  suffering  from  small
tumors  (≤  3  cm  in  diameter,  ≤  3  nodules)  [11].  The  choice
between  resection  and  radiofrequency  ablation  should  be
discussed  on  an  individual  basis,  as  patient  survival  appears
to  be  the  same  for  both  methods.  Radiofrequency  ablation
has  now  overtaken  resection  as  the  reference  treatment
for  unique  nodules  under  2  cm  in  diameter  [12].  The  major
limitation  of  monopolar  radiofrequency  ablation  is  tumor
size,  as  nodules  over  3  cm  in  diameter  are  rarely  entirely
destroyed.  Because  of  this,  other  ablation  methods  are  cur-
rently  being  assessed  [11]  and  multifocal  radiofrequency
ablation  may  allow  tumors  over  3  cm  in  diameter  to  be
treated  curatively  [13].
The  major  disadvantage  of  local  treatments  is  that  they
leave  the  cirrhotic  liver  in  situ, carrying  a  risk  of  tumor
recurrence  (80%  in  5  years)  and  the  other  complications  of
cirrhosis  [6],  which  justify  continuing  the  monitoring  pro-
cess.
Palliative treatment
Arterial  chemoembolization  can  be  used  if  portal  obstruc-
tion  and  hepatic  dysfunction  are  not  present.  The  utility
of  new  chemoembolization  methods  (particularly  DC  Beads)
still  needs  to  be  assessed  [11,14].  Oral  administration  of
sorafenib  is  the  reference  treatment  for  patients  with
good  hepatic  function  in  whom  chemoembolization  is  con-
traindicated  [6].  The  utility  of  Yttrium-90  Microsphere
radioembolization  still  needs  to  be  assessed  [14].rospects  707
revention
he  aim  of  prevention  is  to  avoid  or  delay  the  development
f  HCC  in  chronic  liver  disease.
irological monitoring of chronic HCV or HBV
nfection
irological  recovery  after  antiviral  therapy  in  patients  with
CV  cirrhosis  appears  to  be  associated  with  a large  reduc-
ion  in  the  risk  of  HCC  (by  a  factor  of  4),  even  in  patients
uffering  from  cirrhosis  [15]. The  risk  of  HCC  however  seems
o  be  not  completely  abolished  (cases  have  been  reported
ver  10  years  after  virological  recovery),  justifying  contin-
ed  monitoring.  In  HBV  cirrhosis,  there  also  appears  to  be  a
arge  reduction  in  the  risk  of  developing  HCC  after  antiviral
herapy  [16].
reventative treatments
ltimately,  our  understanding  of  the  mechanisms  of  hepatic
arcinogenesis  should  lead  to  the  use  of  preventative  ther-
pies.  Sorafenib  is  currently  being  assessed  as  secondary
revention  and  metformin,  a  very  widely  used  oral  antidi-
betic  agent,  has  been  shown  to  be  extremely  effective  in
reventing  cancers  from  other  sites.  Its  effect  on  the  devel-
pment  of  HCC  is  going  to  be  tested  in  a  randomized  trial
17]. Statins  may  also  have  preventative  activity  [18].
onclusions and future perspectives
lthough  considerable  advances  have  been  made,  the  over-
ll  survival  of  patients  suffering  from  HCC  has  not  yet  been
mproved  greatly,  although  this  situation  should  change.  The
BV  vaccination  program  and  work  to  combat  contamina-
ion  of  food  by  aﬂatoxin  in  Asia  and  Africa  should  greatly
educe  the  incidence  of  HCC.  Wider  use  of  HCC  screening
n  patients  with  cirrhosis  is  an  important  public  health  chal-
enge  in  industrialized  countries  and  requires  improvement
n  the  detection  of  cirrhosis  in  the  general  population  and
trictly  following  the  HCC  screening  guidelines  [19].
TAKE-HOME  MESSAGES
• HCC  almost  always  develops  in  a  patient  suffering
from  chronic  liver  disease,  usually  at  the  cirrhotic
stage.
• Only  small  HCC  are  amenable  to  curative  therapy,
which  justiﬁes  including  cirrhotic  patients  in  a
periodic  screening  program.
• This  periodic  screening  is  based  on  six  monthly  liver
ultrasound  followed  by  a  diagnostic  procedure  if  a
focal  lesion  is  found.
• The  effectiveness  of  screening  depends  on  identi-
fying  the  target  population  (cirrhosis),  using  appro-
priate  screening  methods  (six  monthly  ultrasound)
and  the  judicious  use  of  the  various  curative
therapies  (specialist  MDT).
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